Other Transaction Agreement W911QY2090013
Award Date
6/24/20
Potential Completion Date
10/31/22
Potential Value
$35M
Funding Federal Agency
Joint PEO Chemical and Biological Defense
Contracting Federal Agency
ACC Aberdeen Proving Ground
Ultimate Awardee
Not listed
NAICS Category
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Competed
Major Defense Program
Not listed
Pricing Type
Other
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Solicitation Procedures
Broad Agency Announcement
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $23,109,340.68 cost-plus-fixed-fee delivery order awarded to Emergent Manufacturing Operations Baltimore LLC, a for-profit limited liability company manufacturer, by the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services. The contract is for the development of a plasma-derived polyclonal antibody-based COVID-19 therapeutic, under the Centers for Innovation in Advanced Development and Manufacturing program. No...
The U.S. Department of Defense's Joint Program Executive Office for Chemical and Biological Defense awarded a $29,929,031.81 Other Transaction Agreement to Just-Evotec Biologics, Inc. to produce monoclonal antibody (mAb) product countermeasures against COVID-19. The contract, awarded on January 15, 2021, has an ultimate completion date of June 30, 2022 and is not set aside for any special business categories. Just-Evotec Biologics, Inc. is a for-profit, foreign-owned manufacturer of goods.
Just-Evotec Biologics, Inc., doing business as Just-Evotec Biologics, has been awarded a $17.9 million other transaction agreement by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to support the production of monoclonal antibody (mAb) countermeasures against COVID-19. The contract will run from July 2020 through February 2022 and will be performed in Seattle, Washington. Under the agreement, Just-Evotec Biologics will leverage its expertise in...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $26.7 million other transaction agreement to America's Blood Centers 501C(6) Trade Association Division, doing business as ABC, to support the "COVID-19" PROTOTYPE PLASMA COLLECTION CAPABILITY. Under this contract, ABC will provide plasma collection services to the Army through October 2021. The work will be performed in West Warwick, Rhode Island. No set aside designation or...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $54.5 million other transaction agreement to Inovio Pharmaceuticals, Inc. to support the development of an electroporation device for COVID-19 prototype efforts. Performance will take place in Plymouth Meeting, Pennsylvania over a two-year period concluding in June 2022. The contract was awarded without any set aside designations to the prime contractor Inovio Pharmaceuticals to develop...
<p>This is a firm fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Cangene Corporation on May 30, 2006. The contract has a ceiling value of $594,219,525.00 and a completion date of December 31, 2027. The place of performance is in Ottawa, Canada. The contract does not have a set-aside designation.</p>
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This is a $2,853,184,716.00 COVID-19 contract awarded by the Joint Program Executive Office for Chemical, Biological, Defensive (JPEO-CBD) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company. The contract is for the procurement of Sotrovimab monoclonal antibodies, an antiviral medication used to treat COVID-19. The contract does not have a set-aside designation. The prime contractor, Glaxosmithkline, LLC, has a history of federal contract awards and grants, primarily...
This $135,212,671.14 federal contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to Gigagen Inc., a for-profit foreign-owned company, for the development of a next-generation recombinant polyclonal antibody discovery platform to produce medical countermeasures. The contract was awarded under BARDA's (Biomedical Advanced Research and Development Authority) Broad Agency...
This firm fixed-price contract, valued at $762,812,695, was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company. The contract is for the development of medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response...